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A B S T R A C T
Purpose: To develop a strategy of achieving targeted collection of endothelial cells (ECs) by endovascular
methods and analyzing the gene expression proﬁles of collected single ECs.
Methods and results: 134 ECs and 37 leukocytes were collected from four patients' intra-iliac artery
endovascular guide wires by ﬂuorescence activated cell sorting (FACS) and analyzed by single-cell
quantitative RT-PCR for expression proﬁle of 48 genes. Compared to CD45+ leukocytes, the ECs expressed
higher levels (p < 0.05) of EC surface markers used on FACS and other EC related genes. The gene
expression proﬁle showed that these isolated ECs fell into two clusters, A and B, that differentially
expressed 19 genes related to angiogenesis, inﬂammation and extracellular matrix remodeling, with
cluster B ECs have demonstrating similarities to senescent or aging ECs.
Conclusion: Combination of endovascular device sampling, FACS and single-cell quantitative RT-PCR is a
feasible method for analyzing EC gene expression proﬁle in vascular lesions.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gene expression studies of patient-derived endothelial cells
(ECs) provide important information regarding the pathogenesis of
many vascular diseases [1–3], in and outside of the central nervous
system. Several groups have reported EC enrichment and
identiﬁcation from endovascular guide wires by 2 EC separation
methods: micropipette picking-up [4] or CD146 antibody-conju-
gated magnetic beads [5–7], both followed by either traditional
gene expression assays like bulk mRNA reverse transcription (RT)
PCR which analyzes RNA extracted from a pool of ECs [4,5],
quantitative RT-PCR [6] or quantitative immunoﬂuorescence [7–
14]. Because of the limitation set by these conventional methods,
only a few (up to 3 or 4) genes can be analyzed. Due to the
complexity and heterogeneity of ECs [15], these studies have
incurred uncertainty and controversy regarding the purity and
functionality of the ECs studied.
Although DNA microarray studies of ECs separated from tissue
can provide high throughput EC gene expression information and
have indicated that heterogeneity of endothelium exists among
different tissues or diseases [15,16], this technique needs bulk
mRNA extracted from at least thousands of ECs, numbers difﬁcult
to attain using endovascular EC sampling methods. Furthermore,
DNA microarray can only analyze gene expression patterns of a
group of ECs and not each individual EC. A more complete picture
of individual EC functional condition in speciﬁc environments
needs an assay, which can analyze the expression proﬁle of
multiple genes in individual ECs.
Recently we reported that EC candidates attached on guide
wires can be collected by ﬂuorescence activated cell sorting (FACS)
and laser capture microdissection. The quality of mRNA extracted
from the ECs is sufﬁcient for analysis of gene expression using
quantitative RT-PCR [17]. Single-cell quantitative RT-PCR
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combined with high-throughput microﬂuidic array technology
facilitates detection of gene expression proﬁles of up to 96 genes in
96 individual cells simultaneously [18,19]. Therefore, it is a
powerful high throughput tool to characterize gene expression
of individual cells.
In this study, we demonstrated that combination of FACS and
high throughput microﬂuidic single-cell quantitative RT-PCR is an
efﬁcient and powerful method for analyzing the changes of EC gene
expression proﬁles in vascular lesions.
2. Material and methods
2.1. Case selection and EC harvest
Samples were collected from four patients undergoing routine
catheter angiography for assessment of cerebrovascular pathology.
The patients provided written consent for the procedure inclusive
of the collection and study of tissues for research purposes
standard on surgical consent forms. ECs were obtained by inserting
a 0.038-inch diameter coaxial curved stainless steel guide wire
(Cook Inc., Bloomington, IN) into the right iliac artery as part of
routine arterial access. Wires are directed under ﬂuoroscopic
visualization so a short (<5 cm) segment of vessel may be
speciﬁcally contacted. The cells attached on the wires were
dislodged by vortexing and centrifuging in a dissociation buffer
(Gibco, Grand Island, NY). After lysing RBC by ACK Lysing Buffer
(Gibco, Grand Island, NY), and centrifuged at 1500 rpm, the pellets
were re-suspended in FACS buffer for incubation of antibodies and
sorting. Experiment design is shown in Fig. 1.
2.2. EC candidate identiﬁcation and sorting on FACS
Single EC candidates were identiﬁed and sorted by a protocol of
seven ﬂuorescently-conjugated monoclonal antibodies on FACS
that we described in our previous study [17]. LIVE/DEAD Fixable
Dead Cell Stain (Life Technologies, Carlsbad, CA) was used to
exclude the dead cells. The antibody information is listed in Table 1.
After staining the dislodged cells with these seven antibodies and
the Amine Aqua Reactive Dye (AmCyan channel), the debris,
doublets and dead cells were excluded before subsequent
procedures (Fig. 2). After excluding CD45+ leucocytes, CD11b+
myeloid cells and CD42b+ platelets by three negative gates, the
remaining cells were gated by four EC speciﬁc surface markers,
CD31, CD34, CD105 and CD146. Cells positive for the 4 EC surface
markers were collected as EC candidates. CD45+ leucocytes were
also collected and used as control. EC candidates and leukocytes
were sorted into 96 well plates on a FACS Aria II (BD Biosciences,
San Jose, CA) with 100 nm nozzle using single cell sort mode.
2.3. Reverse Transcription and cDNA pre-ampliﬁcation
Reverse transcription and cDNA pre-ampliﬁcation were carried
out on a PCR thermocycler. Brieﬂy, each EC candidate was sorted
directly into one well with 9 mL reverse transcription-speciﬁc
target ampliﬁcation (RT-STA) buffer on the 96-well plates
(Eppendoff, Hauppauge, NY). The RT-STA buffer contained 5 mL
CellsDirect 2 Reaction Mix (Life Technologies, Carlsbad, CA),
0.2 mL SuperScript III RT Platinum Taq Mix (Life Technologies,
Carlsbad, CA), 2.8 mL nuclease free water and 1 mL 10 primer
mixture (500 nM) that contained a mix of 48 pairs of primers
speciﬁc to genes listed in Table 2. The primers were custom
designed and all expand introns to minimize the genomic DNA
Fig. 1. Experimental design. Cells were dislodged from the guide wire (1) and were stained by antibodies speciﬁc for different cell surface markers (2). Individual ECs were
sorted into 96-well plates by FACS (3). Speciﬁc gene cDNAs were pre-ampliﬁed by thermocycler (4). Quantitative RT-PCR was performed on Biomark HD system (Fluidigm,
South San Francisco, CA) (5). Data were collected and analyzed by quantitative RT-PCR analysis software (Fluidigm, South San Francisco, CA) (6).
Table 1
Fluorescently conjugated monoclonal antibodies used for EC candidate identiﬁca-
tion on FACS.
Target Format Dilution Vendor Catalog number
CD31 Alexa 647 1:500 BD Biosciences 561654
CD34 PE-Cy7 1:50 Biolegend 343516
CD105 PE-CF594 1:100 BD Biosciences 562380
CD146 PE 1:50 BD Biosciences 561013
CD45 Alexa 700 1:50 Life technologies MHCD4529
CD11b PacBlue 1:50 Biolegend 301324
CD42b FITC 1:50 BD biosciences 555472
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fraction (Fluidigm, South San Francisco, CA). The Fluidigm Assay
IDs listed in Table 2 can be used to obtain primer sequences.
The samples were incubated at 50 C for 15 min for the reverse
transcription, 95 C for 2 min for inactivating reverse transcriptase
and activating Taq polymerase, then subjected to 18 PCR cycles
(95 C 15 sec then 60 C for 4 min for each cycle) for speciﬁc targets
ampliﬁcation (STA). To remove the unincorporated primers for best
results, each sample was then mixed with 3.6 mL exonuclease
treatment buffer composed of 2.52 mL water, 0.36 mL 10
Exonuclease I reaction buffer and 0.72 mL 20 units/ mL Exonuclease
I (New England BioLabs, Ipswich, MA), incubated at 37 C for
30 min for digestion and 80 C for 15 min to inactivate the
exonuclease.
2.4. Quantitative RT-PCR
48.48 nanoﬂuidic chips and a BioMark HD system (Fluidigm,
South San Francisco, CA) were used.Brieﬂy, each pre-ampliﬁed cDNA
sample was diluted by 5 fold in TE Buffer (TEKnova, Hollister, CA).
Then, 2.25mL diluted samples were mixed with 2.5 mL 2x SsoFast
EvaGreen Supermix with Low ROX (Bio-Rad, Hercules, CA) and
0.25 mL 20 DNA Binding Dye Sample Loading Reagent (Fluidigm,
South San Francisco, CA). The pre-mix samples (5 mL each) were
loaded into the 48 sample inlets on the 48.48 Dynamic Array
(Fluidigm, South San Francisco, CA), which had been primed with
control line ﬂuid (Fluidigm, South San Francisco, CA) on IFC
Controller MX (Fluidigm, South San Francisco, CA). Assay Mix
(5 ml) containing 2.5 mL 2 Assay Loading Reagent (Fluidigm, South
San Francisco, CA), 2.25 mL 1 DNA suspension buffer (TEKnova,
Hollister, CA) and 0.25 mL primer set (100 mM) were added to the
48 assay inlets on the 48.48 nanoﬂuidic chip (Fluidigm, South San
Francisco, CA). After loading both pre-mixed samples and the assay
mixtures to the nanochip by IFC Controller MX (Fluidigm, South San
Francisco, CA), the chip was loaded into the BioMark HD system
(Fluidigm, South San Francisco, CA) for PCR through 35 cycles of 5 sec
at 96 C and 20 sec at 60 C after a hot start phase of 60 sec at 95 C.
Fluorescence in the EvaGreen channel was detected and collected by
a CCD camera placed above the chip and 6-carboxy-X-rhodamine
(ROX) intensity was used as normalization.
2.5. Data collection and analysis
Quantitative RT-PCR data of ECs and leukocytes obtained from
4 subjects were analyzed together. Fluidigm quantitative RT-PCR
Analysis software (Fluidigm, South San Francisco, CA) was used to
process RT-PCR data obtained by Biomark HD system and calculate
Ct values. Ct values were further processed in the R statistical
language using algorithms provided by SINGuLAR Analysis Toolset
3.5 (Fluidigm, South San Francisco, CA). All Raw Ct values were
normalized to the assumed detection Ct level of 24 following the
recommendation from this manual. Ct values were converted to
relative expression levels using methods described previously [20].
The assumed minimum value of genes without expression was set
as 10% lower than the lowest recorded reading. Euclidean distance
metric and complete linkage function were used to build the
Hierarchical clustering. Mean-centered data were used for princi-
pal components analysis (PCA) to avoid bias caused by highly
expressed genes.
3. Results
3.1. Selection of genes for proﬁling EC gene expression
Based on previous EC function studies [21,22], we selected three
groups of genes to characterize ECs in this study. They are
19 angiogenesis-related genes, 13 inﬂammation-related genes and
12 extra-cellular matrix (ECM) remodeling-related genes. To
conﬁrm the identity of ECs isolated by FACS, six EC speciﬁc
marker genes and one vascular smooth muscle cell marker gene
(a-actin) were included. We also included the four EC-marker
genes and CD45 that were used for FACS selection of EC candidates
and leukocytes (Table 2).
3.2. The gene expression proﬁle of EC candidates is distinctively
different from that of LCs
A total of 134 EC candidates and 37 leukocytes (LCs) were
collected by FACS through the gating strategy we described
previously [17] and shown in Fig. 2. Among these ECs, 64 (48%)
Fig. 2. FACS gating strategy for EC collection. Seven cell surface markers and one viability marker were used to gate the EC candidates. Cells were ﬁrst gated to exclude debris,
doublets and dead cells identiﬁed by positive Aqua Amine stain. After gating on the viable single cells, the leukocytes (CD45+), macrophages (CD11b+) and platelets (CD42b+)
were eliminated. EC candidates were ﬁrst selected by CD31 and CD34, and then CD105 and CD146.
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expressed three EC markers CD31, CD34 and CD105, and 30 (22%)
expressed four EC markers CD31, CD34, CD105 and CD146.
Furthermore, we compared gene expression proﬁles of EC
candidates and LCs. Among the 11 marker genes, eight were
differentially expressed between the ECs and LCs (Fig. 3). Among
the ﬁve marker genes used in FACS, the expression of the LC marker
CD45 (p = 1.2 1027) was signiﬁcantly higher in LCs than ECs, and
the expression of EC markers, CD31 (p = 0.017), CD34 (p = 3.1 10
5) and CD105 (p = 6.3  107) were signiﬁcantly higher in the ECs
than LCs. The expression of CD146 showed a trend toward higher in
ECs than in LCs (p = 0.15). In addition, compared to LCs, ECs
expressed higher levels of the other four EC speciﬁc genes, VEGFR1
(p = 1.3  108), vWF (p = 2.3  107), Tie1 (p = 1.3  105) and THBD
(p = 0.013). These data indicate that the EC candidates isolated by
FACS were indeed ECs.
3.3. Two EC clusters were identiﬁed based on gene expression proﬁle
Unsupervised hierarchical clustering separated the 134 ECs into
two distinctive clusters according to their expression pattern of the
48 selected functional genes (Fig. 4a). 69 ECs were in cluster A and
65 in cluster B. Principal component analysis (PCA) also showed
two distinct populations and was consistent with hierarchical
clustering. Only three cluster B cells identiﬁed by heat map-based
hierarchical clustering were grouped with cluster A cells in PCA,
and two cluster A cells were grouped with cluster B cells (Fig. 4b).
The correlation of single cell gene expression and different
biological donors was also analyzed by PCA. The 2D PCA
(Fig. 5a) showed that the ECs from different donors did not
overlap and showed no distinguishable cluster. The PCA scree plot
(Fig. 5b) showed the contribution of ﬁrst 10 PCs, which suggested
Table 2
Genes selected for single gene expression analysis.
Gene group Symbol Gene
name
Description Function and reference Fluidigm
assay IDb
Cell marker PTPRCa CD45 Protein tyrosine phosphatase, receptor type C Leucocyte marker GEP00055840
PECAM1a CD31 platelet endothelial cell adhesion molecule-1 Adhesion molecular, inﬂammation [32] GEP00056436
CD34a CD34 Hematopoietic Progenitor Cell Antigen EC marker, inﬂammation [33] GEA00011907
ENGa CD105 Endoglin EC marker, angiogenesis [34] GEP00056632
MCAMa CD146 Melanoma cell adhesion molecule EC marker, inﬂammation [35–38] GEP00056760
KDR Flk1 vascular endothelial growth factor receptor 2 EC marker, angiogenesis [39,40] GEA00012361
FLT1 VEGFR1 vascular endothelial growth factor receptor 1 EC marker, migration [41] GEP00055864
TIE1 Tie1 tyrosine kinase with Ig-like and EGF-like domains 1 EC marker, Angiogenesis [39,42] GEA00012787
THBD – Thrombomodulin EC marker [43] GEA00014984
VWF vWF Von Willebrand factor EC marker, angiogenesis [44] GEA00013832
TEK Tie2 tyrosine kinase with Ig-like and EGF-like domains 2 EC marker, angiogenesis [39,40] GEA00013803
ACTG2 a-actin Actin, gamma-enteric smooth muscle VSMC marker GEA00025197
EPHB2 EphB2 Ephrin type-B receptor 2 Arterial EC marker GEA00029202
EPHB4 EphB4 Ephrin type-B receptor 4 Venous EC marker, angiogenesis [45] GEP00059920
Angiogenesis VEGFA VEGF-A Vascular endothelial growth factor Angiogenesis [40,46,47] GEA00012311
TGFB1 TGF-b1 Transforming growth factor beta1 Modulate angiogenesis [34] GEA00007272
PCNA PCNA Proliferating Cell Nuclear Antigen Proliferation marker [48] GEA00012343
CAT – catalase Oxidative stress & Proliferation [28,49] GEA00023106
SGK1 SGK serum-glucocorticoid-induced protein kinase Proliferation [50] GEP00060290
ANGPT1 – angiopoietin-1 angiogenesis [40,51] GEA00013518
ANGPT2 – angiopoietin-2 Angiogenesis [52] GEP00057393
HIF1A HIF-1a Hypoxia-inducible factor 1-alpha Angiogenesis [53,54] GEA00012495
NR4A1 TR3 human orphan receptor TR3 Proliferation [55] GEA00023496
ALOX5 5-LO 5-lipoxygenase Proliferation [56] GEA00028402
CD44 – Proliferation, angiogenesis [57,58] GEP00056546
ACE – Angiotensin-converting enzyme Angiogenesis [59] GEP00058643
Inﬂammation IL6 – Interleukin 6 Inﬂammation [60] GEA00012521
IL8 – Interleukin 8 Inﬂammation [61] GEA00012363
VCAM1 VCAM-1 vascular cell adhesion molecule 1 Inﬂammation [32] GEP00056408
ICAM1 ICAM-1 Intercellular Adhesion Molecule 1 Inﬂammation[32] GEP00056359
TBXAS1 THA-2 thromboxane synthase-A2 Inﬂammation [62] GEP00060291
NOS3 eNOS endothelial nitric oxide synthase Oxidative stress, Inﬂammation [63,64] GEA00032450
CCL2 MCP-1 monocyte chemoattractant protein 1 Inﬂammation [61,65,66] GEP00055652
SELP – P-selectin Adhesion molecular, Inﬂammation [32] GEA00030146
PTGS1 COX-1 Cyclooxygenase-1 Inﬂammation [67] GEA00027133
PTGS2 COX-2 Cyclooxygenase-2 Inﬂammation [46] GEA00007158
ECM remodeling MMP2 MMP-2 matrix metalloproteinase-2 ECM metabolism [22,53,68] GEA00013719
MMP9 MMP-9 matrix metalloproteinase-9 ECM metabolism, inﬂammation [22] GEA00013721
MMP14 MMP-14 matrix metalloproteinase-14 ECM metabolism [68] GEA00026567
SERPINE1 PAI-1 Plasminogen activator inhibitor-1 ECM metabolism [69,70] GEP00056400
TNF TNF-a Tumor necrosis factor-a ECM metabolism, inﬂammation [68] GEP00059924
ITGA7 – Integrin-a ECM metabolism [71] GEP00058254
TIMP1 TIMP-1 Tissue inhibitor of metalloproteinase 1 ECM metabolism, inﬂammation [72] GEA00007289
TIMP2 TIMP-2 Tissue inhibitor of metalloproteinase 2 ECM metabolism, inﬂammation [73,74] GEA00020949
FN1 – ﬁbronectin ECM metabolism [75] GEA00007778
TNC – Tenasin-C ECM metabolism [76] GEA00031358
SCEL – sciellin ECM metabolism [77] GEA00031897
PPL – periplakin ECM metabolism [77] GEA00032646
a Genes used in FACS.
b Primer sequences for microﬂuidic qPCR can be traced by these company assay IDs.
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Fig. 3. Differential gene expression of ECs and LCs. (a) Violin plots showed the expression of 11 cell-marker genes are different in the ECs (Red) compared with LCs (Green). The
gene name is indicated on top of each violin plot and the value on Y-axle represents the gene expression level in the binary logarithm (log2) value. (b) Bar graph shows the
values of differential gene expression by fold change of the binary logarithm (log2) in ECs relative to LCs (*p < 0.05; ***p < 0.001). Gene symbols are used in the ﬁgures and
corresponding gene names can be found in Table 2. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Two EC clusters were identiﬁed by gene expression proﬁles. (a) Heat map and hierarchical clustering separated the 134 ECs into 2 major clusters, A (n = 69, green
triangle) and B (n = 65, Red circle), based on their expression pattern of the 48 selected genes. (b) 3D PCA plots conﬁrmed the segregation of these two clusters. Cluster A is
annotated by green dots and B by Red dots. Gene symbols are used in the ﬁgures and corresponding gene names can be found in Table 2. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Two clusters identiﬁcation is stronger identiﬁers than donor origin. (a) 2D PCA of the 134 ECs from 4 different donors based on their gene expression proﬁle indicated
no clear cluster separation among donors. (b) PCA scree plot of the ﬁrst 10 PCs suggested the PC1 which identiﬁes the two clusters gives much more contribution to the whole
variance than other PCs.
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the PC1 which identiﬁes the two clusters gives much more
contribution than other PCs.
3.5. Differential gene expression of the 2 EC subsets
Further analysis showed that seven out of the 19 angiogenesis-
related genes were differentially expressed (Fig. 6a Left) by cluster
A and B. Among them, ﬁve were higher in cluster B [vWF
(p = 7.1 1020), CD105 (p = 9.0  1018), TIE1 (p = 1.1 1013), CAT
(p = 7.8  1012) and EPHB4 (p = 9.7  1011)], two were higher in
cluster A [VEGFA (p = 1.2  104) and TGFB1 (p = 0.023)]. Compared
to cluster A, cluster B express higher levels of seven out of
13 inﬂammation-related genes (Fig. 6a Middle), [CD34 (p = 9.0
 1039), P-selectin (p = 9.0  1022), CD31 (p = 1.2  109), CD146
(p = 3.1 107), VCAM-1 (p = 1.4 104), COX2 (p = 0.008) and
ICAM-1 (p = 0.028)], as well as ﬁve out of the 12 ECM remodel-
ing-related genes, were also expressed higher by cluster B than
cluster A cells (Fig. 6a Right), [MMP2 (p = 5.0  1027), PAI-1
(p = 1.7  1015), FN1 (p = 1.1 1015), TIMP1 (p = 2.9  1011) and
TIMP2 (p = 9.5 106)].
4. Discussion
In this study we demonstrated an innovative strategy for
analyzing gene expression proﬁles of ECs collected from vessels on
a single cell level. ECs are collected from endovascular guide wires
through FACS. Single cell gene expression is analyzed using high
throughput microﬂuidic quantitative RT-PCR. This method could
be used to analyze the changes of EC gene expression at single cell
level in vascular lesions. A total of 48 genes in four categories (cell-
marker, angiogenesis, inﬂammation and ECM) were analyzed in
this study. Two distinctive ECs clusters were identify from ECs
collected from normal iliac arteries, suggesting ECs in normal
vessel are heterogeneous.
Researchers who study ECs collected using endovascular
techniques encounter a paradox that more EC marker genes need
to be detected to identify and characterize the collected ECs, while
the EC number harvested from such samples is often too small for
such multiple marker detection. The traditional assays such as bulk
RT-PCR, real-time RT-PCR or quantitative immunocytochemistry
can only detect the mRNA transcription or protein expression of up
to 3–4 EC functional genes, which are not enough for this purpose.
The combination of single EC sorting and high throughput
microﬂuidic quantitative RT-PCR allowed us to check EC identity
through analyzing the expression of both the EC speciﬁc markers
and the expression of functional genes in individual cells
simultaneously. Moreover, because this microﬂuidic quantitative
RT-PCR array technology has 96 gene slots, researchers have much
more ﬂexibility to expand the functional genes studied to help
characterize ECs in varying disease conditions. This technique also
presents a sound basis for comparing EC sampling and characteri-
zation data from different research centers.
Based on gene expression proﬁles, two distinctive clusters were
identiﬁed in ECs collected from normal iliac arteries. A likely
Fig. 6. Differential gene expression of the two EC clusters. (a) Violin plots. Three functional gene groups are included, 19 angiogensis-related genes (Left), 13 inﬂammation-
related genes (Middle) and 12 ECM remodeling genes (Right) of cluster A (green) and cluster B (Red). The gene name is indicated on top of each violin plot and the value on Y-
axle represents the gene expression level in the binary logarithm (log2) value. (b) Bar graph shows the magnitude of differential gene expression by fold change of the binary
logarithm (log2) value in cluster B relative to A (*p < 0.05; **p < 0.01; ***p < 0.001). Gene symbols are used in the ﬁgures and corresponding gene names can be found in
Table 2. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
162 Z. Sun et al. / Biotechnology Reports 7 (2015) 157–165
explanation is that ECs in normal conditions undergo turnover. The
two EC clusters represent ECs at different functional stages, for
example healthy and senescent. ECs are a stable cell type with an
average turnover rate of about three years [23]. Senescent
endothelium has been reported to have decreased expression of
angiogenesis and proliferation genes, attenuated production of
dilating factors and increased expression of contracting factors,
increased oxidative stress, increased production of leukocyte
adhesion-related cytokines or inﬂammation-related cytokines,
and increased apoptosis [23]. Although not typical, cluster B ECs
showed an expression pattern reminiscent of senescence-related
genes like those of previous studies on EC aging and senescence.
These gene expression changes include attenuated gene expres-
sion of VEGF and TGFb1 [24], enhanced expression of CD105 (also a
EC proliferative marker) [25], COX2 [26,27], catalase [28],
VCAM1 and ICAM1 [29], and TIMP2 [30]. Therefore cluster B cells
could represent more mature or aged ECs. It is also of interest that
cluster B ECs showed enhanced EPHB4 expression compared to
cluster A. Although EphB4 is commonly considered a marker for
ECs from veins, there is also data indicating EphB4 is expressed on
both normal arteries and veins [31]. This gives more supportive
evidence that caution should be used when this marker is used to
identify venous ECs. We also ran a comparable volume (50ul) blood
from each of the same patients on FACS and found no ECs. So, it is
unlikely that these ECs came from veins by circulation and
attached to the wire.
A noticeable phenomenon in this study is that only a quarter of
the FACS sorted ECs expressed the four markers used for sorting
and half expressed three. This indicated that FACS sorting cannot
give a 100% pure population and a possible solution for this issue is
the use of FACs machines with Index sorting capabilities. Several
limitations of our study must also be considered. First, the patients
selected for cell collection were not matched for their respective
diseases necessitating angiography, demographic and co-morbid
conditions. Given the small scale and exploratory nature of the
study, controlling for such confounders proved difﬁcult. Despite
the absence of such analysis, when ECs were analyzed as it related
to their patient origin, we noted no signiﬁcant differences by either
PCA or hierarchical clustering. Second, our choice of target genes
for microﬂuidic quantitative RT-PCR was based on literature
searches, introducing unavoidable bias. A more objective selection
of target genes may be possible by analysis of previous microarray
data on ECs. Such analyses are not possible on such small numbers
of cells available, though emerging single cell mRNA sequencing
may give an unbiased view of the global gene expression and
ultimately identify new genes for study. Lastly, EC gene expression
proﬁle analysis was based on fewer than 200 ECs from four
patients. Further studies of single EC gene expression and
transcriptional regulation based on more ECs separated using
endovascular cell collection techniques are necessary to investi-
gate differential gene expression in ECs at different vasculature loci
and in various vascular lesions.
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